In the BioHarmony Drug Report Database

"Preview" Icon

Durvalumab

Imfinzi (durvalumab) is an antibody pharmaceutical. Durvalumab was first approved as Imfinzi on 2017-05-01. It is used to treat transitional cell carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against programmed cell death 1 ligand 1.

 

Trade Name

 

Imfinzi
 

Common Name

 

durvalumab
 

ChEMBL ID

 

CHEMBL3301587
 

Indication

 

non-small-cell lung carcinoma, transitional cell carcinoma
 

Drug Class

 

Monoclonal antibodies: fully human, immunomodulating

Image (chem structure or protein)

Durvalumab structure rendering